The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients – a systemic review and meta-analysis of randomized controlled trials

References

• Lee GE, Lorch SA, Sheffler-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126:204–213. doi:10.1542/peds.2009-310920643717
   PubMed Web of Science ®Google Scholar
• Lautz TB, Raval MV, Barsness KA. Increasing national burden of hospitalizations for skin and soft tissue infections in children. J Pediatr Surg. 2011;46:1935–1941. doi:10.1016/j.jpedsurg.2011.05.00822008331
   PubMed Web of Science ®Google Scholar
• Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs. 2003;5 Suppl 1:35–46.14632104
   PubMedGoogle Scholar
• Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46 Suppl 5:S368–S377. doi:10.1086/53359318462092
   PubMed Web of Science ®Google Scholar
• Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:e25–e76. doi:10.1093/cid/cir53121880587
   PubMed Web of Science ®Google Scholar
• David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616–687. doi:10.1128/CMR.00081-0920610826
   PubMed Web of Science ®Google Scholar
• Shirley DA, Heil EL, Johnson JK. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther. 2013;2:95–110. doi:10.1007/s40121-013-0010-x25134474
   PubMedGoogle Scholar
• Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN, Sader HS. Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States Hospitals: 2012-2014. Pediatr Infect Dis J. 2017;36:486–491. doi:10.1097/INF.000000000000147728403050
   PubMed Web of Science ®Google Scholar
• Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother. 2011;66 Suppl 3:iii69–iii80. doi:10.1093/jac/dkr10121482572
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant staphylococcus aureus and streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008-2010). Clin Infect Dis. 2012;55 Suppl 3:S206–S214. doi:10.1093/cid/cis56322903953
   PubMed Web of Science ®Google Scholar
• Sader HS, Mendes RE, Farrell DJ, Flamm RK, Jones RN. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012). Pediatr Infect Dis J. 2014;33:837–842. doi:10.1097/INF.000000000000030725222304
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE ceftaroline surveillance program. Clin Infect Dis. 2012;55 Suppl 3:S181–S186. doi:10.1093/cid/cis56022903950
   PubMed Web of Science ®Google Scholar
• Cannavino CR, Nemeth A, Korczowski B, et al. A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone. Pediatr Infect Dis J. 2016;35:752–759. doi:10.1097/INF.000000000000115927093162
   PubMed Web of Science ®Google Scholar
• Blumer JL, Ghonghadze T, Cannavino C, et al. A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia. Pediatr Infect Dis J. 2016;35:760–766. doi:10.1097/INF.000000000000116027078119
   PubMed Web of Science ®Google Scholar
• Korczowski B, Antadze T, Giorgobiani M, et al. A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection. Pediatr Infect Dis J. 2016;35:e239–e247. doi:10.1097/INF.000000000000119127164462
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration‘s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. doi:10.1136/bmj.d592822008217
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Safety, tolerability and efficacy of ceftaroline in paediatrics with late-onset sepsis In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 NLM Identifier: NCT2424734 Available from: https://clinicaltrials.gov/show/NCT2424734.
   Google Scholar
• Forest Laboratories. Ceftaroline diffusion into cerebrospinal fluid of children In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 NLM Identifier: NCT2600793 Available from: https://clinicaltrials.gov/show/NCT2600793
   Google Scholar
• Baylor College of Medicine. Ceftaroline for treatment of hematogenously acquired Staphylococcus aureus osteomyelitis in children In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 NLM Identifier: NCT2335905 Available from: https://clinicaltrials.gov/show/NCT2335905
   Google Scholar
• Sotgiu G, Aliberti S, Gramegna A, et al. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. Respir Res. 2018;19:205. doi:10.1186/s12931-018-0905-x30352588
   PubMed Web of Science ®Google Scholar
• Karve S, Hackett J, Levinson J, Gibson E, Battersby A. Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections. J Comp Eff Res. 2016;5:393–405. doi:10.2217/cer-2015-002426946948
   PubMed Web of Science ®Google Scholar